Transaction Details
On October 7, 2026, Stefan A. Dyckerhoff, a director of Astera Labs Inc. (NASDAQ: ALAB), disposed of 12,499 shares of the company’s common stock at $376.06 per share, generating proceeds of $4,700,373. The sale was executed under a Rule 10b5‑1 trading plan adopted on December 1, 2025. The shares sold comprised 3,505 shares held directly, 8,333 shares held indirectly through a trust for which Mr. Dyckerhoff serves as trustee, and 661 shares held indirectly through a limited partnership in which a trust for which he is trustee acts as the general partner.
Recent Acquisition
On October 1, 2026, Mr. Dyckerhoff acquired 68 shares of common stock at $311.57 per share. These shares were awarded as restricted stock units (RSUs) under Astera Labs’ 2024 Stock Option and Incentive Plan, issued in lieu of cash compensation for his quarterly non‑employee director retainer fees. The RSUs will vest 100 % on the three‑month anniversary of the Vesting Commencement Date of August 15 2026, provided his continuous service with the company is maintained. Each RSU confers the right to receive one share of common stock.
Post‑Transaction Holdings
Following the transactions, Mr. Dyckerhoff directly holds 47,019 shares of Astera Labs common stock, which includes shares to be issued upon vesting of the RSUs. Indirectly, he holds approximately 286,400 shares through a trust, 2,648 shares through a limited partnership, and additional shares through several irrevocable trusts. He disclaims beneficial ownership of the indirectly held shares except to the extent of his pecuniary interest.
Company Performance Highlights
Astera Labs reported second‑quarter 2026 results that beat Wall Street expectations. Adjusted earnings per share were $0.80, exceeding the consensus forecast of $0.69 by 15.9 %. Revenue reached a record $392.4 million, a 104 % increase year‑over‑year, driven by strong demand across its product lines. Needham raised its price target to $425 from $260, maintaining a Buy rating, and highlighted product growth, particularly the ramp‑up of Scorpio X switches expected in the second half of 2026. Northland upgraded the stock to Outperform from Market Perform, setting a price target of $350 and citing optimism on AI infrastructure spending and anticipated earnings revisions as Scorpio‑X ramps.
Analyst Commentary
InvestingPro notes that the stock appears overvalued relative to its fair value, with a high price‑to‑earnings ratio of 168. The firm offers additional ProTips and research reports for Astera Labs and other U.S. equities.